Call for a dedicated European legal framework for bacteriophage therapy

Archivum Immunologiae et Therapiae Experimentalis

Volumn 62, Issue 2, 2014, Pages 117-129

  Verbeken, Gilbert ^a,b   Pirnay, Jean Paul ^a   Lavigne, Rob ^c   Jennes, Serge ^a   De Vos, Daniel ^a   Casteels, Minne ^b   Huys, Isabelle ^b  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c LABORATORY OF GENE TECHNOLOGY   (Belgium)

Author keywords

Bacteriophage; European; Human; Legal; Legislation; Regulatory; Therapy

Indexed keywords

ADVANCED THERAPY MEDICINAL PRODUCT; BIOLOGICAL MEDICINAL PRODUCT; BIOLOGICAL PRODUCT; HUMAN MEDICINAL PRODUCT; TOXIN; UNCLASSIFIED DRUG; VACCINE;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; CARCINOGENESIS; DRUG CLASSIFICATION; DRUG LEGISLATION; DRUG MARKETING; DRUG MECHANISM; DRUG NOMENCLATURE; DRUG RESEARCH; EUROPE; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MEDICINAL SPECIES; NONHUMAN; REGULATORY FRAMEWORK; REVIEW; SEPTIC SHOCK; VIROTHERAPY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; BIOTECHNOLOGY; CODES OF ETHICS; DRUG RESISTANCE; EUROPEAN UNION; HUMANS;

EID: 84896549652     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-014-0269-y     Document Type: Review

References (28)

1. Ackermann HW (2012) Who went into phage research? Bacteriophage 2:55-59
2. Brüssow H (2005) Phage therapy: the Escherichia coli experience. Microbiology 151(Pt 7):2133-2140
3. Brüssow H (2012) What is needed for phage therapy to become a reality in Western medicine? Virology 434:138-142
4. Bruttin A, Brüssow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874-2878 (Pubitemid 40917605)
5. Caplin J (2009) Bacteriophage: old treatment, new focus? Microbiologist 10:20-23
6. Cooper MA, Shlaes D (2011) Fix the antibiotic pipeline. Nature 472:32
7. Gill JJ, Hyman P (2010) Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:2-14
8. Górski A, Miȩdzybrodzki R, Borysowski J et al (2009a) Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 10:766-774
9. Górski A, Targońska M, Borysowski J et al (2009b) The potential of phage therapy in bacterial infections of the eye. Ophthalmologica 223:162-165
10. Krylov V (2011) Use of live phages for therapy in a background of co-evolution of bacteria and phages. Int Res J Microbiol 2:315-332
11. Kutateladze M, Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591-595
12. Kutter E, De Vos D, Gvasalia G et al (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69-86
13. Levin BR, Bull JJ (2004) Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2:166-173 (Pubitemid 39490070)
14. Maura D, Debarbieux L (2011) Bacteriophages as twenty-first century antibacterial tools for food and medicine. Appl Microbiol Biotechnol 90:851-859
15. Merabishvili M, Pirnay JP, Verbeken G et al (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4:e4944
16. Miȩdzybrodzki R, Borysowski J, Weber-Dabrowska B et al (2012) Clinical aspects of phage therapy. Adv Virus Res 83:73-121
17. Monk AB, Rees CD, Barrow P et al (2010) Bacteriophage applications: where are we now? Lett Appl Microbiol 51:363-369
18. Parracho HM, Burrowes BH, Enright MC et al (2012) The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Gen Med 6:279-286
19. Payne RJ, Jansen VA (2003) Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 42:315-325 (Pubitemid 36433874)
20. Pirnay JP, De Vos D, Verbeken G et al (2011) The phage therapy paradigm: Prêt-à-porter of sur-mesure? Pharm Res 28:934-937
21. Pirnay JP, Verbeken G, Rose T et al (2012) Introducing yesterday's phage therapy in today's medicine. Future Virol 7:379-390
22. Scanlan PD, Buckling A (2012) Co-evolution with lytic phage selects for the mucoid phenotype of Pseudomonas fluorescens SBW25. ISME J 6:1148-1158
23. Silverman D (2010) Doing qualitative research. Saga, London
24. Soothill J (2013) Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections. Expert Rev Anti Infect Ther 11:909-1015
25. Thiel K (2004) Old dogma, new tricks - 21st century phage therapy. Nat Biotechnol 22:31-36
26. Verbeken G, Pirnay JP, De Vos D et al (2012) Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 60:161-172
27. Wittebole X, De Roock S, Opal SM (2013) A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. doi:10.4161/viru.25991
28. Wright A, Hawkins CH, Änggård EE et al (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistent Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349-357